Coronavirus company news summary – FDA provides EUA for Biohit’s antibody test kit – Brite-Strike Technologies develops UVC medical device

24 June 2020 (Last Updated June 24th, 2020 09:22)

MBio Diagnostics has received a contract worth $629,595 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop and commercialise the point-of-care multiplex serology test to identify human anti-SARS-CoV-2 antibodies. MBio will now be able to finish the panel development and file for Emergency Use Authorisation (EUA).

The US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to Biohit’s Sars-CoV-2 IgM/IgG antibody test kit. With this authorisation, the test kit can be used in CLIA-certified labs. The SARS-CoV-2 IgM/IgG Antibody Test Kit is said to have shown high IgM and IgG sensitivity and high specificity. The test also provides results within few minutes.

Brite-Strike Technologies has developed a UVC medical device that adds pathogen killing technology for N95 face masks. The micro device can be fitted on any N95 or a mask similar to the Under Armour Sportsmask and used along with hydrogen peroxide and a heat source to decontaminate it.

IgNova has filed a patent application for the use of passive immunisation to control SARS-CoV-2 infection. The company carried out research on technology for specific egg immunoglobulins (IgY). The IgY binds the spike protein of SARS-CoV-2 and neutralises the virus when it enters the body. The technology provides a safe, economical, and unlimited source of polyclonal antibodies to control the Covid-19 virus.